MAR 10, 2017
Glaucoma 360, 2017
Cornea/External Disease, Dry Eye , Glaucoma, IOP and Aqueous Flow, Medical Therapy
Some studies estimate that 40% to 50% of glaucoma patients have dry eye syndrome, much of it induced by the medications ophthalmologists prescribe to treat their disease. In this interview from Glaucoma 360, Dr. Richard Lewis discusses some of the new dry eye therapies, including a novel device he thinks will be a game changer. TrueTear is a handheld device that stimulates nerves in the nose to induce tear production. Recently acquired by Allergan, the device is expected to soon be approved by the FDA. Lewis, who served as a clinical trial investigator, said his patients were so pleased with the results they refused to give back the device.